3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer’s Disease with APP Osaka Mutation

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We previously identified a novel mutation in amyloid precursor protein from a Japanese pedigree of familial Alzheimer’s disease, FAD (Osaka). Our previous positron emission tomography (PET) study revealed that amyloid β (Aβ) accumulation was negligible in two sister cases of this pedigree, indicating a possibility that this mutation induces dementia without forming senile plaques. To further explore the relationship between Aβ, tau and neurodegeneration, we performed tau and Aβ PET imaging in the proband of FAD (Osaka) and in patients with sporadic Alzheimer’s disease (SAD) and healthy controls (HCs). The FAD (Osaka) patient showed higher uptake of tau PET tracer in the frontal, lateral temporal, and parietal cortices, posterior cingulate gyrus and precuneus than the HCs (>2.5 SD) and in the lateral temporal and parietal cortices than the SAD patients (>2 SD). Most noticeably, heavy tau tracer accumulation in the cerebellum was found only in the FAD (Osaka) patient. Scatter plot analysis of the two tracers revealed that FAD (Osaka) exhibits a distinguishing pattern with a heavy tau burden and subtle Aβ accumulation in the cerebral cortex and cerebellum. These observations support our hypothesis that Aβ can induce tau accumulation and neuronal degeneration without forming senile plaques.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

          Soluble oligomers are common to most amyloids and may represent the primary toxic species of amyloids, like the Abeta peptide in Alzheimer's disease (AD). Here we show that all of the soluble oligomers tested display a common conformation-dependent structure that is unique to soluble oligomers regardless of sequence. The in vitro toxicity of soluble oligomers is inhibited by oligomer-specific antibody. Soluble oligomers have a unique distribution in human AD brain that is distinct from fibrillar amyloid. These results indicate that different types of soluble amyloid oligomers have a common structure and suggest they share a common mechanism of toxicity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A specific amyloid-beta protein assembly in the brain impairs memory.

            Memory function often declines with age, and is believed to deteriorate initially because of changes in synaptic function rather than loss of neurons. Some individuals then go on to develop Alzheimer's disease with neurodegeneration. Here we use Tg2576 mice, which express a human amyloid-beta precursor protein (APP) variant linked to Alzheimer's disease, to investigate the cause of memory decline in the absence of neurodegeneration or amyloid-beta protein amyloidosis. Young Tg2576 mice ( 14 months old) form abundant neuritic plaques containing amyloid-beta (refs 3-6). We found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-beta assembly, which we term Abeta*56 (Abeta star 56). Abeta*56 purified from the brains of impaired Tg2576 mice disrupts memory when administered to young rats. We propose that Abeta*56 impairs memory independently of plaques or neuronal loss, and may contribute to cognitive deficits associated with Alzheimer's disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

              Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.
                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                22 June 2020
                June 2020
                : 21
                : 12
                : 4443
                Affiliations
                [1 ]Department of Radiology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; h.shimada@ 123456med.osaka-cu.ac.jp
                [2 ]Department of Neurology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; m4518413@ 123456med.osaka-cu.ac.jp (S.M.); jun-t@ 123456med.osaka-cu.ac.jp (J.T.); a-taked@ 123456med.osaka-cu.ac.jp (A.T.)
                [3 ]Department of Nuclear Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; kawabe@ 123456med.osaka-cu.ac.jp
                [4 ]RIKEN Center for Biosystems Dynamics Research, Kobe 650-0047, Japan; yasuwada@ 123456riken.jp (Y.W.); a.mawatari@ 123456riken.jp (A.M.); yywata@ 123456riken.jp (Y.W.)
                [5 ]Department of Functional Brain Imaging Research (DOFI), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba 263-8555, Japan; shimada.hitoshi@ 123456qst.go.jp (H.S.); higuchi.makoto@ 123456qst.go.jp (M.H.); suhara.tetsuya@ 123456qst.go.jp (T.S.)
                [6 ]Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; tomi@ 123456med.osaka-cu.ac.jp
                Author notes
                Author information
                https://orcid.org/0000-0003-4911-9320
                https://orcid.org/0000-0003-2096-1602
                https://orcid.org/0000-0002-7139-7178
                https://orcid.org/0000-0001-5731-798X
                Article
                ijms-21-04443
                10.3390/ijms21124443
                7352205
                32580499
                df03f810-4bae-4b1b-9a5f-31b07f1efeca
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 27 May 2020
                : 19 June 2020
                Categories
                Case Report

                Molecular biology
                amyloid pet,tau pet,amyloid precursor protein,mutation,familial alzheimer’s disease,cerebellum,pbb3,pib

                Comments

                Comment on this article